Jupiter Asset Management Ltd. Sells 424,240 Shares of Bristol Myers Squibb Company $BMY

Jupiter Asset Management Ltd. cut its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 31.7% during the third quarter, HoldingsChannel.com reports. The firm owned 914,115 shares of the biopharmaceutical company’s stock after selling 424,240 shares during the period. Jupiter Asset Management Ltd.’s holdings in Bristol Myers Squibb were worth $41,227,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Norges Bank acquired a new position in shares of Bristol Myers Squibb in the 2nd quarter valued at $1,554,154,000. Charles Schwab Investment Management Inc. increased its stake in Bristol Myers Squibb by 16.8% in the second quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company’s stock valued at $3,277,456,000 after acquiring an additional 10,195,775 shares during the period. Arrowstreet Capital Limited Partnership raised its position in Bristol Myers Squibb by 428.5% in the second quarter. Arrowstreet Capital Limited Partnership now owns 11,311,281 shares of the biopharmaceutical company’s stock worth $523,599,000 after purchasing an additional 9,171,098 shares in the last quarter. Man Group plc lifted its stake in Bristol Myers Squibb by 280.4% during the second quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock worth $345,594,000 after purchasing an additional 5,503,391 shares during the period. Finally, Franklin Resources Inc. boosted its holdings in Bristol Myers Squibb by 142.8% during the second quarter. Franklin Resources Inc. now owns 8,436,811 shares of the biopharmaceutical company’s stock valued at $390,541,000 after purchasing an additional 4,961,869 shares in the last quarter. 76.41% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Sanford C. Bernstein reissued a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 3rd. HSBC reiterated a “hold” rating and set a $53.00 price objective on shares of Bristol Myers Squibb in a research note on Wednesday, December 10th. The Goldman Sachs Group restated a “neutral” rating and issued a $57.00 target price (up previously from $51.00) on shares of Bristol Myers Squibb in a research note on Tuesday, December 2nd. Barclays started coverage on shares of Bristol Myers Squibb in a report on Thursday. They issued an “overweight” rating and a $75.00 target price on the stock. Finally, Cantor Fitzgerald reissued a “neutral” rating on shares of Bristol Myers Squibb in a report on Monday, November 24th. Nine analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $60.19.

Bristol Myers Squibb Trading Up 1.0%

BMY opened at $60.32 on Friday. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $63.33. The stock has a market capitalization of $122.85 billion, a PE ratio of 17.49, a PEG ratio of 0.17 and a beta of 0.29. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32. The firm has a 50-day moving average price of $56.05 and a two-hundred day moving average price of $49.86.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The company had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. During the same period last year, the company earned $1.67 earnings per share. Bristol Myers Squibb’s revenue for the quarter was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd were given a dividend of $0.63 per share. The ex-dividend date was Friday, January 2nd. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. Bristol Myers Squibb’s dividend payout ratio is presently 73.04%.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: FDA accepted BMY’s NDA for an iberdomide combination in relapsed/refractory multiple myeloma and granted priority review (decision due Aug. 17, 2026). This raises the chance of a new revenue stream and short/medium‑term upside if approved. FDA Accepts BMY’s NDA
• Positive Sentiment: Coverage highlighting iberdomide review and BMY’s AI alliance frames new upside scenarios beyond core franchises — supportive sentiment for medium‑term growth prospects. Iberdomide Review And AI Alliance Add New Angles To BMY Outlook
• Positive Sentiment: Analyst commentary continues to underscore BMY’s durable oncology franchise as a core strength, which supports baseline cash flow and reduces execution risk relative to smaller biotech peers. Oncology Franchise Remains A Core Strength
• Neutral Sentiment: Coverage noting BMY’s relative stability vs. the broader market — useful context for defensive positioning but not an immediate catalyst. BMY Delivers Stability While S&P 500 Stays Volatile
• Neutral Sentiment: General “street” roundups summarize mixed analyst views; useful for gauging sentiment but contain no single market‑moving surprise. What Does The Street Have To Say About BMY?
• Negative Sentiment: Zacks Research issued multiple downward revisions to quarterly and FY2027 EPS (examples: Q1 2026 cut to $1.40 from $1.50; Q3 2027 to $1.51 from $1.57; FY2027 to $5.71 from $5.90). Those cuts signal the analyst community trimming growth/earnings expectations and are the primary near‑term negative driver weighing on the stock.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.